Wei Li

Wei Li, Ph.D., possesses extensive experience in the biotechnology field, currently serving as Chief Scientific Officer at Cytovia Therapeutics and holding board memberships at NAYA Biosciences and CytoLynx Therapeutics. Additionally, Wei Li contributes to the Scientific Advisory Board of Artus Therapeutics and has served as Chief Development Officer at OliX Pharmaceuticals, Inc. Wei Li's academic background includes a Postdoctoral fellowship in Rheumatology at Harvard Medical School and a Ph.D. in Molecular Virology from Georgia State University.